1. Scrip
  2. >>R&D
  3. >>Pipeline Watch

Pipeline Watch: Nine Approvals And 13 Phase III Readouts

The Week In R&D

 
• By Scrip Team

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Image
• Source: Alamy

The table above records the past week’s major catalyst events that occurred in the late-stage pipeline during the past week (see table for relevant dates), created using Citeline’s Biomedtracker.

The table lists drugs at Phase II or above for which an important catalyst was recorded during the week, according...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pipeline Watch

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: Seven Approvals And Thirteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: Eight Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch: Eight Approvals And Five Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

More from Clinical Trials

Pipeline Watch: Six Approvals And Twenty Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

QL Biopharm’s Zovaglutide Offers Potentially Safer Once-Monthly Obesity Option

 
• By Dexter Jie Yan

Zovaglutide tied Amgen’s MariTide in weight reduction at Week 24 in a Phase II study, but with a potentially better safety profile. However, efficacy versus existing once-weekly drugs is a remaining question.

Regeneron To Pit Lynozyfic Against J&J’s Darzalex In Smoldering Myeloma

 
• By Alaric DeArment

The drugmaker presented positive Phase II data for its BCMAxCD3-directed bispecific in high-risk smoldering myeloma patients.